CTOs on the Move

Specific Diagnostics

www.specific.com

 
Bloodstream infection leading to sepsis is responsible for more than half of all deaths in hospitals and is the most expensive condition treated in hospitals. Mortality rate increases 6% every hour from onset. Therefore, it is critical the right antibiotic treatment is determined quickly. Current methodologies require 3 days to determine the effective antibiotic. Specific Diagnostics has developed a new technology that determines the effective antibiotic in less than 1 day. Specific`s Reveal™ instrument and assay are cost effective and labor-saving allowing clinics to readily deploy the Specific Reveal solution. Specific`s unique patented technology leverages a low-cost small molecule sensor ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Beltone

Beltone is a Glenview, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Implant Direct, LLC

Implant Direct, LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Oncologix

Oncologix is a diversified medical device and healthcare holding company. For its customers, Oncologix provides FDA approved medical devices and state licensed healthcare services. For its shareholders, Oncologix acquires profitable operations that build, maintain and nourish shareholder value. The Company`s corporate mission is to be the best small cap medical device and healthcare holding company in North America.

Perspective Therapeutics

We develop game-changing therapies that make an impactful difference for cancer patients and the clinicians who treat them.

Cytrellis

Cytrellis is a medical technology company dedicated to the development and commercialization of first-in-class aesthetic devices which emphasize safety, efficacy, and improved quality of life for our patients. Cytrellis` first product, the ellacor® System with Micro-Coring™ Technology, is indicated for use by medical professionals for the treatment of moderate to severe wrinkles in the mid to lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV. Ellacor provides aesthetic practitioners with an unprecedented ability to improve age-related changes in skin and to help restore youthful beauty.